Effects of second-generation TKIs in KCL22-R and -S cell line. KCL22-S, -R, -R^SHP2−, and R^SHP−1+ cell lines are cultured for 48 hours in the presence of clinical relevant dose of IMA (5μM), dasatinib (50nM), and nilotinib (150nM), and cell viability was assessed by trypan blue exclusion. Results are expressed as mean ± SD of 3 independent experiments. (A) KCL22-S cell line shows a significant reduction in cell viability after 48 hours of TKI treatments (51% ± 3%, 20% ± 9%, and 50% ± 7% of cell viability after IMA, dasatinib, and nilotinib treatments, respectively). (B) Cell viability of KCL22-R is not significantly modified by 48 hours of TKI treatments (88% ± 2%, 70% ± 4%, and 70% ± 4% of cell viability after IMA, dasatinib, and nilotinib treatments, respectively). (C) KCL22-R^SHP2− cell line shows a significant reduction in cell viability after 48 hours of TKI treatments (50% ± 4%, 30% ± 5%, and 45 ± 6% of cell viability after IMA, dasatinib, and nilotinib treatments, respectively). (D) KCL22-R^SHP−1+ cell line shows a significant reduction in cell viability after 48 hours of TKI treatments (40% ± 2%, 20% ± 9%, and 10% ± 7% of cell viability after IMA, dasatinib, and nilotinib treatments, respectively).